NeuVasQ: An innovative approach to fight against neurovascular and neurodegenerative diseases
NeuVasQ was founded based on new insights into the molecular mechanisms maintaining the integrity of the blood-brain barrier (BBB) generated by the laboratory of Prof. Benoit Vanhollebeke.(WELBIO ULB). The BBB regulates the exchange between the vascular system and central nervous system (CNS). Increased BBB permeability, due to age or injury, is involved in many neurological conditions through the leakage of harmful blood substances into the CNS. BBB dysfunction is a factor in many neurodegenerative disorders, such as Alzheimer’s, as well as multiple acute neurological conditions like stroke and epilepsy.
With this EUR 20 million Series A, NeuVasQ aims to identify the most promising indications for clinical trials, focusing on a range of neurodegenerative disorders and acute neurological disorders. As part of these exploratory studies, NeuVasQ will also consider various innovative therapeutic modalities, including gene and mRNA therapy.
More info : https://neuvasq.com/
Source : Press release Newton Biocapital